

(19) AUSTRALIAN PATENT OFFICE

- (54) Title
Sterol enriched mixed lammellarity Amphotericin intercalating liposomes in saline and the process for their preparation
- (51)⁶ International Patent Classification(s)
A61K 9/127 (2006.01) ^{8BMEP} **A61K**
A61K 31/7048 31/7048
(2006.01) 20060101ALI2005100
A61K 9/127 ^{8BMEP}
20060101AFI2005100 PCT/IN2005/000193
- (21) Application No: 2005251572 (22) Application Date: 2005 .06 .13
- (87) WIPO No: W005/120460
- (30) Priority Data
- | | | |
|---------------|--------------|--------------|
| (31) Number | (32) Date | (33) Country |
| 1113/Del/2004 | 2004 .06 .11 | IN |
- (43) Publication Date : 2005 .12 .22
- (71) Applicant(s)
Lifecare Innovations Pvt. Ltd
- (72) Inventor(s)
Verma, Lily; Tripathi, Krishan Kumar; Verma, Jitendra Nath
- (74) Agent/Attorney
Wrays, 56 Ord Street, West Perth, WA, 6005
- (56) Related Art
MEHTA R. et al., Biochemica Et Biophysica Acta, 1984, vol. 770, no. 2, pp 230-234
US 4 766 046 A
SZOKA F. C Jr et al., Antimicrobial Agents and Chemotherapy, 1987, vol. 31, no. 3, pp 421-429

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 December 2005 (22.12.2005)

PCT

(10) International Publication Number
WO 2005/120460 A1

(51) International Patent Classification⁷: A61K 9/127,
31/7048

SI, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IN2005/000193

(22) International Filing Date: 13 June 2005 (13.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1113/Del/2004 11 June 2004 (11.06.2004) IN

(71) Applicants and

(72) Inventors: VERMA, Jitendra, Nath [IN/IN]; c/o Lifecare Innovations Pvt. Ltd., B-589 Sushant Lok - 1, Gurgaon, Haryana 122 002 (IN). VERMA, Lily [IN/IN]; c/o Lifecare Innovations Pvt. Ltd., B-589 Sushant Lok - 1, Gurgaon, Haryana 122 002 (IN). TRIPATHI, Krishan, Kumar [IN/IN]; E-20, Type D1 Quarters, HUDCO Place, Andrewsganj, New Delhi 110 049 (IN).

(74) Agents: ANAND, Pravin et al.; Anand And Anand Advocates, B-41 Nizamuddin East, New Delhi 110 013 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STEROL ENRICHED MIXED LAMELLARITY AMPHOTERICIN INTERCALATING LIPOSOMES IN SALINE AND THE PROCESS FOR THEIR PREPARATION

(57) Abstract: The present invention relates to sterol enriched mixed lamellarity Amphotericin intercalating liposomes in saline for treatment of infections primarily parasitic infection especially those caused by intracellular protozoan parasites. The invention further relates to increasing circulation time of the drug encapsulated in the liposomes in the blood by subjecting liposomal pharmaceuticals to sonication before administration.

WO 2005/120460 A1

STEROL ENRICHED MIXED LAMELLARITY AMPHOTERICIN INTERCALATING LIPOSOMES IN SALINE
AND THE PROCESS FOR THEIR PREPARATION

FIELD OF INVENTION:

The invention relates to sterol enriched mixed lamellarity
10 Amphotericin intercalating liposomes in saline and the process of
preparing it.

BACKGROUND OF THE INVENTION:

Leishmaniasis is caused by macrophage resident intracellular
protozoan parasites *Leishmania donovani*, *Leishmania infantum* and
15 *Leishmania chagasi*. Parasite transmission occurs through the bite of
infected female phlebotomine sandfly. Sandfly obtains infected blood
while sucking the blood from their parasite carrier hosts. Four different
forms of Leishmaniasis with different clinical manifestations occur in
humans. Of these different forms, Visceral Leishmaniasis (VL), which is
20 also known as kala-azar is the most severe and has a mortality rate of
almost 100% if not treated. Frequent bouts of fever, weight loss,
enlargement of spleen and liver accompanied with anemia are
characteristic signs and symptoms of Visceral Leishmaniasis.

Amphotericin B is a polyene antibiotic produced by soil bacteria
25 *Streptomyces nodosus*. Amphotericin B is known to be the most potent
antifungal drug since its discovery in 1950s. Later it was found to be an
effective treatment for kala-azar also (Trans Royal Soc. Trop. Med. Hyg.
1963; 57: 266-268).

Unlike alarming incidents of resistance against commonly used
30 and first line drugs viz. Sodium Stibogluconate and Pentamidine,
Amphotericin B is free of drug resistance problems (CP Thakur *et.al.*

- 5 1993. The National Medical Journal of India; 6: 57-60 and CP Thakur *et.al.* 1993. Indian Journal of Medical Research; 97: 170-175).

Despite being an effective anti-lieshmanial drug, amphotericin B has been used cautiously only as second line drug due to it's infusion related adverse effects and toxicities, predominantly nephrotoxicity, cardio-
10 toxicity and neuro-toxicity. As no other drug could replace the broad spectrum and the potency of amphotericin B, understandably, various strategies have been experimented and even practiced with limited success to overcome dose related toxicities of amphotericin B.

The most unscientific, ambiguous, unacceptably inconsistent, and
15 therefore least practiced way to overcome amphotericin B related toxicity is to heat, cool and then administer conventional amphotericin B. There have been clinical trials for evaluation of benefits of combining Intralipid (an IV lipid suspension) with conventional amphotericin B as a substitute for true lipid formulations of amphotericin B (Dupont B.
20 2002, J. Antimicrobial Chemotherapy; 49, Suppl. S1, 31-36).

In one such comparative study on 82 children employing amphotericin B deoxycholate suspension alone and its mixture with Intralipid, no benefit of mixing was found in improving safety or tolerance of amphotericin B (Nath, CE *et.al.* 1999, Antimicrobial Agents
25 and Chemotherapy; 43: 1417-1423). Both forms of amphotericin B were comparatively evaluated in another study on adults patients, and the observations revealed that there is no significant difference in nephrotoxicity in the groups administered amphotericin B with or without Intralipid (Nucci, M *et.al.*1999, Antimicrobial Agents and
30 Chemotherapy; 43: 1445-1448).

Besides the lack of advantage of Intralipid admixture, there are significant problems associated with administration of amphotericin B-

5 Intralipid mixture. These are: lower therapeutic activity, thrombocytopenia, liver function abnormalities, cholestasis and pulmonary toxicity (Deray, G. 2002, J. Antimicrobial Chemotherapy; 49, Suppl. S1, 37-41).

10 Yet another alternative usually considered for reducing toxic effects of amphotericin B is infusion at slower rate. Although, a prospective study concluded that slower infusion rate did not reduce Amphotericin B toxicity (Ellis, M.E. 1992, Antimicrobial Agents and Chemotherapy; 36: 172-179), in patients with renal insufficiency, rapid infusion is advised to be avoided to overcome severe hyperkalaemia and
15 potentially fatal arrhythmia (Bell, N.H. *et.al.* 1962, American Journal of Medicine; 340:64-69 and Craven P.C. 1985, Antimicrobial Agents and Chemotherapy; 27:868-871). The toxicities of amphotericin B are so critical that with very limited and incremental advantages also, slow infusion of all formulations of amphotericin B has become a standard
20 practice.

Adverse effects of amphotericin B have been successfully overcome, however, by lipid formulations of amphotericin B (Sunder S and Murray HW, 1996: 173: 762-765 and Seaman *et. al.* 1995; 21: 188-193). Liposomal amphotericin B is now established as the most effective and
25 safe drug which is also free of drug resistance problems.

Strategic suitability of liposomal formulations of amphotericin B for the treatment of Visceral Leishmaniasis emanates from several factors including factors such as leishmania resides in the scavenger cells such as macrophages, liposomes are rapidly taken up by the
30 macrophages, amphotericin B is an effective anti-leishmanial drug, and amphotericin B can be formulated as liposomal preparation. All of these facilitate targeted delivery of Liposomal amphotericin B to the desired

5 site of anti-parasitic action and reduce toxicities of amphotericin B. Additionally liposomes offer an amplification effect through concentrated encapsulation of numerous molecules of drug in each liposome particle, which are delivered at the site of action (Gregoriadis G, 1995. Engineering liposomes for drug delivery: Progress and
10 Problems. TIBTECH; 13: 527-537). Prevention of toxicity by encapsulating amphotericin B in liposomes has made liposomal amphotericin B the best option for the treatment of Visceral Leishmaniasis.

The critical lipid constituent for minimizing amphotericin B
15 toxicity of formulations for use in treatment of systemic mycosis, are sterols. Of the sterols available for formulations, cholesterol, cholesterol succinate and cholesteryl sulphate have been used in experimental and/or commercial amphotericin B lipid preparations. Formulations of amphotericin B constituted of ergosterol with certain phospholipids
20 have been reported to cause lysis of red cells *in-vitro* and thus believed to be unsuitable (Mehta, R. *et.al.* 1984, Biochimica et Biophysica Acta; 770: 230-234).

Unsuccessful attempts with limited number of phospholipid combinations and ergosterol has prevented further efforts on
25 development of ergosterol containing amphotericin B formulations (New, P.R.C. *et.al.* 1981, J. Antimicrobial Agents and Chemotherapy; 8: 371-381 and Graybill, J.R. *et.al.* 1982, J. Infectious Diseases; 145: 748-752)

Cytolytic action of amphotericin B is mediated through the interaction of amphotericin B with the sterols present in the cells. The
30 drug has stronger affinity to the ergosterol, a major constituent of fungal cell membranes (Szoka, F.C. and Tang, M. 1993, J. Liposome Research; 3:363-375) and precursor of ergosterol present in kala-azar causing

5 parasite *Leishmania* (Meyerhoff, A.1999, Clinical Infectious Diseases; 28:
42-48) than to cholesterol, a sterol present in most mammalian cell
membranes. Binding of amphotericin B with sterols in the cell
membranes, results in pore formation, causing cytolytic action of the
drug. Both, the therapeutic antimicrobial action and toxicity to the
10 mammalian cells are caused by the same mechanism.

In order to reduce toxicity to the host cell achieved by targeting
the pathogen and avoidance of the mammalian host, cholesterol
containing liposomes emerged as matchless strategy for the treatment of
systemic mycosis with even aggressive treatment with high doses up to
15 15mg/kg body wt/day. For such aggressive treatment it would seem
that a better approach would be to administer formulations with higher
concentration of amphotericin B. Apparent concerns of toxicities
expected from concentrated preparations of amphotericin B, have
restricted all preparations of amphotericin B to 1mg/ml with
20 recommendations to infuse slowly.

Such concerns of amphotericin B toxicity assume more
significance for treatment of leishmaniasis caused by macrophage
resident intracellular parasite with liposomal amphotericin B.
Liposomes are known to be rapidly phagocytosed in macrophages and
25 will obviously result in concentration of liposome encapsulated
amphotericin B in the macrophages. To formulate liposomes with higher
concentration of amphotericin B without causing toxicity required
strategies, which are not yet reported.

Understanding of sterol synthesis is important for rational
30 designing of quick, effective and specific treatment of leishmaniasis
using liposomal amphotericin B. Lipids account for 15% of the dry
weight of the leishmanial cells (Meyer and Ilolz, 1966, J. Biol. Chem. 24:

5000-5007). Metabolism of lipids is crucial for several vital physiological processes and effect parasite's survival. Ergosterol or its precursor episterol is synthesized *de novo* from AcetylCoA to evalonate to Squalene to Lanosterol followed by four more steps to finally Ergosterol (Coppens and Courtoy. 1995, Mol. Biochem. Parasitol. 73,179- 188 and Patent No. US 6,403,576B1).

It is pertinent to note that Leishmania require cholesterol for their sustenance and fulfill their requirement by salvaging cholesterol from their host macrophage cells. Effective drug designing prudently shall involve adversely effecting survival of Leishmania by depriving Leishmania of their cholesterol requirement.

Delivery of cholesterol containing liposomes through phagocytic action of reticuloendothelial cells to some extent negates the benefits of targeted delivery of amphotericin B in the macrophage, the home of Leishmania.

Administration of 20-21 mg of Amphotericin B in shorter durations also results in administration of sucrose undesirable in diabetics. Mixture of conventional Amphotericin B with 0.9 % Sodium Chloride is known to result in precipitation of Amphotericin B (Martindale, p315). Furthermore, mono and disaccharides such as glucose, mannitol, trehalose, sucrose and lactose are also reported to render stability to liposomal formulations (US Patent No.5,180,713). These observations have argued against use of Sodium Chloride solution for suspension of liposomal amphotericin B and directions for use advise against use of saline (AmBisome product information).

SUMMARY OF THE INVENTION:

The present invention may provide a solution to any one or more of the following objects;

a sterol enriched mixed lammellarity amphotericin intercalating liposomes for treatment

of infections for targeted delivery of liposomal amphotericin B thereby reducing toxicities of amphotericin B; or

a liposomal amphotericin B with suitable replacement of cholesterol. Cholesterol is normally used for preventing leakiness of liposomal drugs / vaccines and in case of amphotericin B formulations cholesterol is used for targeting and minimizing drug toxicities. Cholesterol, however, supports leishmania survival inside the host, therefore should not be taken as constituent of formulation; or

the delivery of a higher concentration of amphotericin B to the target area without causing toxicity; or

the ability to sonicate liposomal pharmaceuticals before administration to increase the plasma half-life of the liposomal drug for facilitating better bio-distribution in the body; or

to provide a sugar free composition containing liposomal amphotericin B and therefore freely usable by diabetics; or

to provide a pharmaceutical composition with advantageous properties.

To achieve to aforementioned objects the instant invention provides for sterol enriched mixed lamellarity Amphotericin intercalating liposomes in 0.9% saline wherein the concentration of Amphotericin B is 1 to 15 mg/ml for treatment of infections. There is high Amphotericin B concentration in liposomes.

More specifically, there is provided sterol enriched mixed lamellarity Amphotericin B intercalating liposomes in an aqueous suspension wherein the concentration of Amphotericin B is 1 to 15 mg/ml and the aqueous suspension is a suspension in an aqueous solution of 0.9% sodium chloride without a buffer for use in treatment of infections.

2005251572 27 Jan 2010 5

The sterol is ergosterol with or without cholesterol. The sterol are in combination with phospholipid. The said phospholipid is phosphatidylcholine. The ergosterol constitutes 50% of the total lipid of the liposome. One example of the preferred ratio of phosphatidylcholine, ergosterol and amphotorecin B is 5 : 2 : 1.

- 5 Sonication before administration increases plasma half-life and provides for better bio distribution.

DETAILED DESCRIPTION OF THE INVENTION:

- Choice of lipid constituents of liposomes particularly sterol is critical to prudent designing of potently effective and safe anti-
10 leishmanial drug. Inclusion of appropriate sterol is necessary to prevent binding of liposomal amphotericin B to mammalian host cells. Delivery of cholesterol in macrophage home of Leishmania through the phagocytic uptake of cholesterol containing liposomal amphotericin B negates optimal benefits of targeted delivery of amphotericin B. Another
15 sterol option of ergosterol in combination with certain lipids in liposomes as outlined above has been shown to cause toxicity to red blood cells *in-vitro*. This invention was taken up to design cholesterol free and suitable sterol containing liposomal amphotericin B.

- Ergosterol with or without cholesterol and in combination with
20 phospholipids such as phosphatidylcholine irrespective of their fatty acid compositions from either synthetic or from natural sources such as Soy in a range of ratios was found suitable for formulating liposomal amphotericin B which is safe and potently effective against infections such as Leishmania. Amphotericin B concentration range was used
25 between 1-15 mg /ml of the final preparation. The lipids i.e. phospholipids preferably phosphatidylcholine and ergosterol are taken in such ratios where ergosterol constitutes up to 50 molar % of the total lipids of the liposomal formulations. One preferred formulation for example is PC: Ergosterol : Amphotericin B in the molar ratio of 5:2:1 in
30 aqueous medium.

Amphotericin B is well documented to precipitate in saline. Amphotericin B in liposomes of phospholipid compositions reported

5 herein above are stabilized and no precipitation occurs even on long
term storage. The invention permits replacement of dextrose with saline
with or without buffers. One preferred example is to use 0.9 % Sodium
Chloride for suspension of liposomal amphotericin B. Such liposomal
formulations are stable both in suspension or when stored after
10 lyophilization.

Alternatively, lyophilized Liposomal Amphotericin B may be
reconstituted in aqueous solutions such as 0.9% Sodium Chloride.

The process of preparing the liposomal Amphotericin B is
explained but not limited by the following examples.

15 Liposomes can be manufactured by employing a variety of
methods either alone or in combination (Szoka, F. Jr. and
Papahadjopoulos, D., 1980. Ann. Rev. Biophys. Bioeng. 9: 467-508).

Example 1. Methanolic solution of the Liposomal constituents are
evaporated to give a film of the constituents. This film is hydrated using
20 aqueous solutions and multilamellar Liposomes are produced by
sheering of the film.

Example 2. Methanolic solution of the Liposomal constituents are
processed in Spray Dryer and then hydrated and reconstituted in
aqueous medium of choice to give mixed lamellar Liposomal
25 preparation.

Example 3. Methanolic solution of the Liposomal constituents are
evaporated to give a film of the constituents, aqueous solution of choice
is added and then subjected to Sonication resulting predominantly into
Unilamellar Liposomal Preparation.

30 **Bio-therapeutic properties**

Ergosterol-PC Liposomes with higher concentration of Liposomes
are well tolerated and have been found to be safe with respect to both

chronic and acute toxicity. These Liposomal formulations with up to 15mg Amphotericin B/ml of preparations could be administered without any infusion related adverse effect. LD₅₀ of these formulations is higher than reported for Cholesterol-PC liposomal amphotericin B.

5 Nephrotoxicity was determined by measuring changes in serum creatinine value at various time periods after the administration of this drug. Serum Creatinine value remained significantly unaltered for up to the administration of complete dosage i.e. 21mg/ kg body weight required for complete treatment of Leishmaniasis.

0 Leishmania are completely cleared using any of the concentrated Amphotericin B encapsulated Ergosterol-PC Liposomes after administration of 21mg of Amphotericin B in liposomes reported herein. Only in few cases, additional dose of Liposomal Amphotericin B was required for complete parasite clearance.

5 To support the findings, a tolerance study was conducted in mice using the sterol composition of the instant invention prepared as described herein. A higher concentration of Amphotericin B of up to 10mg. per ml. was administered. The tolerance studies indicate that 100 mg Amphotericin B /kg as a single dose in the ergosterol for the liposomal formulation was well tolerated.

20 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

25 Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application, or patent cited in this text is not repeated in this text is merely for reasons of conciseness.

2005251572 27 Jan 2010

Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or was known in Australia or any other country.

REFERENCES:

- 5 Nath, CE *et.al.* 1999, Antimicrobial Agents and Chemotherapy; 43: 1417-1423
- Ellis, M. E. 1992, Antimicrobial Agents and Chemotherapy;36: 172- 179
- Bell, N.H. *et al.*1962, American Journal of Medicine; 340:64-69

5 Craven P.C.1985, Antimicrobial Agents and Chemotherapy;
27:868-871

We Claim:

1. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes in an aqueous suspension wherein the concentration of Amphotericin B is 1 to 15 mg/ml and the aqueous suspension is a suspension in an aqueous solution of 0.9% sodium chloride without a buffer for use in treatment of infections.
2. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 wherein the said sterol is ergosterol with or without cholesterol.
3. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 wherein the sterol is in combination with phospholipid.
4. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 3 wherein the said phospholipid is phosphatidylcholine.
5. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 wherein ergosterol constitutes up to 50 molar % of the total lipid of the liposome.
6. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 to 4 wherein the ratio of phosphatidylcholine, ergosterol and Amphotericin B is 5:2:1.
7. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 wherein the infection is due to intracellular protozoan parasite including leishmania.
8. Sterol enriched mixed lamellarity Amphotericin B intercalating liposomes as claimed in claim 1 wherein the said composition is sonicated during manufacturing and before administration for increasing plasma half-life and better bio-distribution.